 The FDA has signed off Seres Therapeutics Incs NASDAQ: MCRB Investigational New Drug IND application for SER-155 to initiate Phase 1 trial. SER-155 is a cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal antibiotic-resistant bacterial infections, bacteremia, and graft-versus-host disease GvHD. 